<DOC>
	<DOCNO>NCT02147197</DOCNO>
	<brief_summary>This study evaluate superiority ulipristal acetate vs. placebo treatment bleed associate uterine fibroid</brief_summary>
	<brief_title>A Study Efficacy Safety Single Ulipristal Treatment Course Treatment Abnormal Uterine Bleeding Associated With Leiomyomas</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<criteria>Premenopausal woman , 1850 year , inclusive . Has experience cyclic abnormal uterine bleeding ( heavy prolong ) . Has menstrual blood loss ( MBL ) â‰¥ 80 mL measure alkaline hematin method screen first 8 day menses . Has minimum one discrete leiomyoma observable transvaginal ultrasound screen assessment Has history uterine surgery would interfere study endpoint . Has know coagulation disorder include bleed disorder clot disorder ( e.g. , von Willebrand disease platelet disorder , factor V Leiden , prothrombin gene mutation , antiphospholipid syndrome ) . Has history , current uterine , cervix , ovarian , breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>